TMCnet News
54gene Announces Leadership Changes in Mission to Transform Diversity of Genomics Research Data54gene, Inc. a health data technology company on a mission to transform racial disparity in genomics research data globally, today announced leadership changes that position the company to pursue new strategic partnerships and raise additional capital. The following leadership changes were announced:
"54gene is solving the issue of racial disparity in genomics data and paving the way for more inclusive healthcare outcomes," said Oke. "With committed investors and partners in Africa and globally, we are solely focused on 54gene's original mission and building a distinct and unprecedented platform in its diversity and scale." 54gene aims to significantly improve the inclusion of data from African populations in genomics research. Most genomic data used for development research today is from Europe and North America, while less than 3% is from Africa. Increasing access to genomic data from African populations will improve the effectiveness and relevance of products to the health of African people and power therapeutic discoveries benefiting all populations. The company's 600,000-sample capacity biobank, which already holds 130,000 samples, is the largest commercial biobank in Africa and one of the most diverse in the world. Through its robust partner and clinical network on the continent, 54gene has access to millions of patients to support its mission. To date, the company has raised $45 million dollars from leading investors including Adjuvant Capital, V8 Capital, KdT Ventures, and Cathay AfricInvest Innovation Fund. About 54gene: 54gene is a health data technology company on a mission to transform racial disparity in genomics research data globally. Founded in 2019, the company generates actionable genetic insights from research cohorts in the world's most genetically diverse populations to improve the development, availability, and efficacy of therapeutics, vaccines, and diagnostics that benefit all populations. Follow us at https://54gene.com/ and on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005161/en/ |